Dumont Cyrielle, Chenel Marylore, Mentré France
a Université Paris Diderot, Sorbonne Paris Cité , UMR 738, INSERM, Paris , France.
J Biopharm Stat. 2014;24(3):471-92. doi: 10.1080/10543406.2014.888443.
Nonlinear mixed-effect models are used increasingly during drug development. For design, an alternative to simulations is based on the Fisher information matrix. Its expression was derived using a first-order approach, was then extended to include covariance and implemented into the R function PFIM. The impact of covariance on standard errors, amount of information, and optimal designs was studied. It was also shown how standard errors can be predicted analytically within the framework of rich individual data without the model. The results were illustrated by applying this extension to the design of a pharmacokinetic study of a drug in pediatric development.
非线性混合效应模型在药物研发过程中的应用越来越广泛。在设计方面,一种替代模拟的方法基于费舍尔信息矩阵。其表达式通过一阶方法推导得出,随后扩展到包含协方差,并在R函数PFIM中实现。研究了协方差对标准误差、信息量和最优设计的影响。还展示了如何在丰富个体数据框架内无需模型即可通过解析方法预测标准误差。通过将此扩展应用于儿科药物研发中药代动力学研究的设计,对结果进行了说明。